首页|Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO(2)Life (R) (M101)

Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO(2)Life (R) (M101)

扫码查看
原文链接
  • NSTL
  • Elsevier
Background: Infection with SARS-CoV-2 is responsible for the COVID-19 crisis affecting the whole world。 This virus can provoke acute respiratory distress syndrome (ARDS) leading to overcrowed the intensive care unit (ICU)。 Over the last months， worldwide experience demonstrated that the ARDS in COVID-19 patients are in many ways "atypical"。 The mortality rate in ventilated patients is high despite the application of the gold standard treatment (protective ventilation， curare， prone position， inhaled NO)。 Several studies suggested that the SARS-CoV-2 could interact negatively on red blood cell homeostasis。 Furthermore， SarsCov2 creates Reactive Oxygen Species (ROS)， which are toxic and generate endothelial dysfunction。

HypoxemiaCOVID-19Oxygen CarrierHEMO2LifeM101SARS-CoV-2

Lupon, Elise、Lellouch, Alexandre G.、Zal, Franck、Cetrulo, Curtis L., Jr.、Lantieri, Laurent A.

展开 >

Univ Toulouse III Paul Sabatier, Dept Plast Surg, Toulouse, France

Harvard Med Sch, Vascularized Composite Allotransplantat Lab, Ctr Transplantat Sci, Massachusetts

Aeropole Ctr, Dept HEMARINA SA, Biotechnopole, Morlaix, France

Univ Paris, European George Pompidou Hosp, Dept Plast Surg, Paris, France

展开 >

2021

10.1016/j.mehy.2020.110421

Medical hypotheses

Medical hypotheses

SCI
ISSN：0306-9877
年,卷(期)：2021.146
  • 2
  • 64